Compare AbbVie Inc (ABBV) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs NICE Ltd — how do they compare? AbbVie Inc trades at $254.14 (market cap $449.91B), while NICE Ltd trades at $97.35 (market cap $5.88B). The key difference: AbbVie Inc is far larger — about 76.5× NICE Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| ABBV | NICE | |
|---|---|---|
Market Cap | $449.91B | $5.88B |
Sector | Health | Technology |
52-Week High | $261.07 | $171.98 |
52-Week Low | $184.85 | $83.15 |
Enterprise Value | $513.38B | $5.66B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
NICE trades at $97.17, up 0.44% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong profitability with a 65.79% gross margin and 17.57% net income margin, while recent news highlights AI platform expansions with Sopra Steria and AWS European Sovereign Cloud deployment (Business Wire, 2026-07-01).
The stock presents a compelling value opportunity with a P/E of 11.53 below sector averages, supported by a $124.88 analyst price target implying 28% upside. Risks include projected net income decline to $530M in 2026 and overbought short-term RSI levels. Wall Street sentiment remains positive with 13 buy ratings and no sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
